Serina Therapeutics, Inc.SEREarnings & Financial Report
Serina Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapies for neurological and inflammatory disorders. It leverages its proprietary polyrozaxamer platform to enhance drug efficacy, safety and bioavailability, advancing lead candidates for Parkinson's disease and chronic pain for global specialty pharma markets.
SER Q4 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
N/A
Net Profit
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
Serina Therapeutics, Inc. Q4 FY2025 Financial Summary
Serina Therapeutics, Inc. reported revenue of $0 for Q4 FY2025, with a net profit of N/A (down 21.8% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | N/A |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Serina Therapeutics, Inc. Annual Revenue by Year
Serina Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $130.0K).
Serina Therapeutics, Inc. Quarterly Revenue & Net Profit History
Serina Therapeutics, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | N/A | N/A |
| Q3 FY2025 | $0 | — | $-4.6M | N/A |
| Q2 FY2025 | $130.0K | +154.9% | $-6.4M | -4960.0% |
| Q1 FY2025 | $0 | — | $-4.8M | N/A |
| Q2 FY2024 | $51.0K | +628.6% | $5.2M | 10203.9% |
| Q3 FY2023 | $29.0K | +222.2% | $1.8M | 6041.4% |
| Q1 FY2023 | $30.0K | +500.0% | $1.7M | 5526.7% |
Income Statement
| Q1 2023 | Q3 2023 | Q2 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $30000 | $29000 | $51000 | $0 | $130000 | $0 | $0 |
| YoY Growth | 500.0% | 222.2% | 628.6% | N/A | 154.9% | N/A | N/A |
Balance Sheet
| Q1 2023 | Q3 2023 | Q2 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $12.5M | $12.2M | $10.7M | $6.7M | $8.9M | $12.4M | $7.0M |
| Liabilities | $32.5M | $3.9M | $27.1M | $5.2M | $7.3M | $10.8M | $7.0M |
| Equity | $-36.1M | $-27.5M | $-16.4M | $1.7M | $1.8M | $1.8M | $-37000 |
Cash Flow
| Q1 2023 | Q3 2023 | Q2 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-709000 | $-1.0M | $-8.0M | $-4.3M | $-3.8M | $-3.9M | $-18.0M |